(Q30886413)

27 June 2017

1 reference

1 reference

1 reference

title

The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis (English)

1 reference

major depressive disorder

27 June 2017

1 reference

1 reference

1 reference

1

1 reference

27 June 2017

Richard A Hansen

3

0 references

Bradley N. Gaynes

object named as

Bradley N Gaynes

series ordinal

4

0 references

author name string

Kylie Thaler

series ordinal

2

1 reference

27 June 2017

publication date

1 January 2009

1 reference

27 June 2017

1 reference

27 June 2017

volume

32

1 reference

27 June 2017

issue

12

1 reference

27 June 2017

page(s)

1159-1173

1 reference

Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11318930-000000000-00000

Evaluating non-randomised intervention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318930-000000000-00000

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318930-000000000-00000

Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318930-000000000-00000

Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine

21 January 2018

1 reference

12 December 2020

Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.

1 reference

12 December 2020

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

1 reference

12 December 2020

Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression

1 reference

12 December 2020

Duloxetine in the long-term treatment of major depressive disorder

1 reference

12 December 2020

Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years

1 reference

12 December 2020

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials

1 reference

12 December 2020

Duloxetine for the treatment of major depressive disorder in older patients

1 reference

12 December 2020

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

12 December 2020

Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction

1 reference

12 December 2020

Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.

1 reference

12 December 2020

Duloxetine for the treatment of major depressive disorder.

1 reference

12 December 2020

Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat).

1 reference

12 December 2020

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

1 reference

12 December 2020

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

1 reference

12 December 2020

Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat

1 reference

12 December 2020

Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose

1 reference

12 December 2020

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

12 December 2020

Current methods of the US Preventive Services Task Force: a review of the process

1 reference

12 December 2020

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder

1 reference

12 December 2020

Are some antidepressants better than others?

1 reference

12 December 2020

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

1 reference

12 December 2020

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

1 reference

12 December 2020

Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study

1 reference

12 December 2020

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

12 December 2020

The economic burden of depression in the United States: how did it change between 1990 and 2000?

1 reference

12 December 2020

Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis

1 reference

12 December 2020

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.

1 reference

12 December 2020

Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder

1 reference

12 December 2020

Australian and New Zealand clinical practice guidelines for the treatment of depression

1 reference

12 December 2020

Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine

1 reference

12 December 2020

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder

1 reference

12 December 2020

Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil

1 reference

12 December 2020

An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies

1 reference

12 December 2020

Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder

1 reference

12 December 2020

Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder

1 reference

12 December 2020

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder

1 reference

12 December 2020

Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).

1 reference

12 December 2020

The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity

1 reference

12 December 2020

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

1 reference

12 December 2020

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

1 reference

12 December 2020

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

12 December 2020

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

1 reference

12 December 2020

Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression

1 reference

12 December 2020

Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder

1 reference

12 December 2020

Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder

1 reference

12 December 2020

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

1 reference

12 December 2020

Reading and critically appraising systematic reviews and meta-analyses: a short primer with a focus on hepatology

1 reference

12 December 2020

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial

1 reference

12 December 2020

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder

1 reference

12 December 2020

Duloxetine in the Treatment of Major Depressive Disorder

1 reference

12 December 2020

Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms

1 reference

12 December 2020

Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.

1 reference

12 December 2020

Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.

1 reference

12 December 2020

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.

1 reference

12 December 2020

10.2165/11318930-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 June 2017

1029639529

0 references

1 reference